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ABSTRACT: 
Silencing of the B lymphocyte-induced maturation protein 1 (Blimp-1), a pivotal 
transcriptional regulator during terminal differentiation of B cells into plasma cells with 
siRNAs is under investigation as novel therapeutic approach in Primary Effusion Lymphoma 
(PEL), a HHV-8 related and aggressive B cell Lymphoma currently lacking of an efficacious 
therapeutic approach.   
The clinical application of small interfering RNA (siRNA) in cancer therapy is limited by the 
lack of an efficient systemic siRNA delivery system. 
In this study we aim to develop pegylated siRNA lipoplexes formed using the cationic lipid 
DOTAP and DSPE-PEG2000, capable to effectively stabilize anti Blimp-1 siRNA and suitable 
for systemic administration. 
Two types of pegylated lipoplexes using a classic (C-PEG Lipoplexes) or a post-pegylation 
method (P-PEG-Lipoplexes) were formulated and compared in their physicochemical 
properties (size, zeta potential, morphology and structure) and efficiency on PEL cell lines.  
A stable siRNAs protection was obtained with post pegylation approach (2% molar of DSPE-
PEG2000 respect to lipid) resulting in structures with diameters of 300 nm and a complexation 
efficiency higher that 80% (0.08 nmol/10 nmol of lipid). In vitro studies on PEL cell lines 
suggested that empty liposomes were characterized by a low cell toxicity also after PEG 
modification (cell viability and cell density over 85% after treatment with 10 µM of lipid).    
We demonstrated that P-PEG-Lipoplexes were able to significantly reduce the levels of 
BLIMP-1 protein leading to reduction of viability (less that 15% after transfection with 100 
nM of complexed siRNAs) and activation of apoptosis.   
In vitro efficiency encourage us to further test the in vivo potential of P-PEG-Lipoplexes in 
PEL therapy. 	
	
	
	
	
	
	
	
	
	
  
	
INTRODUCTION:	
Increasing knowledge of the genetic basis of cancer has accelerated the application of siRNA, 
a small interfering double-stranded RNAs able to inhibit protein expression in a sequence 
dependent manner through degradation and/or blockage of the corresponding mRNA, as a 
new generation of cancer therapeutics [1]. However, the future of such gene-based 
therapeutics is dependent on achieving successful stability and delivery. To date, in vivo 
systemic delivery of siRNA-based therapeutics to tumor cells remains a challenge.  
Accumulation of drugs after systemic administration in lymphoma as in solid tumors takes 
advantage of the increased vascular permeability of new angiogenic vessels, called enhanced 
permeability and retention (EPR) effect [2-3]. Unfortunately, siRNA is not stable in 
bloodstream as after injection it is subjected to a rapid enzymatic degradation by endogenous 
nucleases and siRNA is rapidly taken up by phagocytes and aggregated with serum proteins 
with a consequent short half-life (~ 0.3 h) [4]. Extensive research is ongoing regarding the 
design and assessment of non-viral delivery technologies for siRNA to treat a wide range of 
cancers [5-7]. 
Different types of polymeric and lipidic nanocarriers were designed to overcome this 
problems by protecting siRNAs and improving their uptake into the target cells; generally, 
these systems differ for efficiency and safety profile [8]. Cationic liposomes emerged as one 
of the most attractive carriers, able to electrostatically interact with siRNA molecules, 
forming stable lipoplexes that need to be optimized in term of size, surface charge and 
structure, in order to efficiently deliver gene material into cells [9-11]. 
Formulation of siRNA with positively charged vectors is used to neutralize the overall surface 
charge and thereby increase cellular internalization.  
We have recently demonstrated efficient tumor cell apoptosis after intraperitoneally 
administration of siRNA/DOTAP lipoplex in a Primary Effusion Lymphoma (PEL) animal 
model [12]. PEL is a B-cell non-Hodgkin lymphoma involving the serous cavities invariably 
associated with Human HerpesVirus-8 (HHV-8) in which the standard chemotherapy is often 
inefficacious with consequent low prognoses (median survival time shorter than 6 months) 
[13].  
Rapid uptake by reticuloendothelial system (RES), aggregation [14-16] and adverse effects 
related to the cationic charge (inflammatory toxicity, hepatotoxicity, leukopenia and 
thrombocytopenia) were described in literature [17-18]. This aspect could affect the 
possibility to administer cationic lipoplex by intravenous route (IV).  
  
The improvement of lipoplex therapy under in vivo condition is largely dependent on the 
development of a strategy able to simultaneously mask the cationic charge, avoid RES uptake 
and increase the half life supporting the passive targeting into the tumor. This goal is typically 
achieved by the addition of a PEG moiety [19-22].   
Unfortunately, the steric hindrance produced by the PEG molecules on the liposomal surface 
could affect the formation and the stabilization of lipoplexes as well as siRNA endosomal 
escape [23-26]. This discrepancy concerning pegylation in siRNA delivery systems is 
described as the “PEG-dilemma” [27].  
Thus, the pegylation of siRNA lipoplexes should be carefully optimized. Different strategies 
to insert PEG on a lipidic construct were investigated. PEG lipo-polymer (CHOL-PEG or 
DSPE-PEG) directly incorporated into the lipidic layer or adsorbed on the surface are 
typically used. Alternatively, as innovative strategy the use of cleavable PEG was developed 
as this molecules were incorporated into the liposomes conferring them stealth propriety, to 
finally been removed once into the cell by response of local tumor environment (typically a 
reduction in pH) [28-29]. 
Notwithstanding interesting preliminary results were achieved, a higher depth investigation 
should be devoted both to the toxicity profile of those new molecules and to the tumor 
selectivity.  
On the bases of these premises, this article aimed to focus the attention on technological 
optimization of pegylated cationic lipoplexes applicable for IV administration of anti-BLIMP-
1 siRNAs, formed using DOTAP (cationic lipid recently approved for clinical trials [30]) and 
a FDA approved PEG lipid (DSPE-PEG). Two different approaches are described to insert 
PEG moieties on cationic surface of lipoplexes, namely the conventional (C-PEG) and the 
post-pegylation (P-PEG) process. Along with the physicochemical properties (size, zeta 
potential, morphology and structure) of the colloidal delivery systems, both siRNA loading 
and efficiency to mediate gene silencing in PEL cells were evaluated.  
 
 
2. MATERIALS AND METHODS: 
2.1 Materials 
N-[1(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride salt (DOTAP, 
C42H80ClNO4; Mol.Wt. 698.54 Da) was obtained from Avanti Polar-Lipids (Alabaster, AL, 
USA) and N-(carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine, sodium salt (DSPE-PEG2000, C133H263NO55PNa,  Mol.Wt. 2779 Da) 
  
was kindly grafted from Lipoid (Steinhausen, ZG, Switzerland). PRDM1/Blimp-1 stealth 
select RNAi was purchased from Invitrogen (Milan, Italy). It was composed of three non-
overlapping sequences of 25nt with the following sense targeting sequence: siRNAa [5’-
gcgacgaagccaugaaucucauuaa-3’], siRNAb [5’-ggccuuucaaaugucagacuugcaa-3’], siRNAc [5’-
cagaacgggaugaacaucuacuucu-3]. Cell culture medium generally used for the culture of human 
normal and neoplastic leukocyte (RPMI 1640), fetal bovine serum (FBS), and phosphate 
buffered saline (PBS) pH 7.4 were purchased from Euroclone Celbio (Milan, Italy). 
7-aminoactinomycin D (7AAD) was obtained from BD Biosciences (Mississauga, ON, 
Canada). Antibody for Blimp-1, C14A4 and βTubulin, 9F3 were purchased from Cell 
Signaling Technology (Danvers, MA, USA). RNAse free water was purchased from Sigma-
Aldrich (Milan, Italy). A MilliQ water system, supplied with distilled water, provided high 
purity water (18 MΩ). All other chemicals were commercially obtained as reagent grade 
products and used without any further purification. 
CRO-AP/3 and BCBL-1 cell lines were commercially provided by Leibniz Institute DSMZ 
(Braunschweig, Germany), DSMZ n° ACC 683; ACC 275 respectively. 
 
2.2 Preparation of Liposomes (Liposome, C-PEG-Liposome, P-PEG-Liposome) 
All liposomes were prepared by a thin layer evaporation method followed by an extrusion 
procedure. 
Cationic liposome (Liposome) was formulated dissolving DOTAP (5 mg) in chloroform (2.5 
mL). The solvent was removed by rotary evaporation (B-480 Büchi, Buchs, SG, Switzerland) 
at 20 ± 1°C for 1 h and 10 mbar followed by 3 h at 0.15 mbar. The dry lipidic film was then 
hydrated with 5 mL of RNAse free water preheated to 40 ± 2°C. The hydrated lipidic film 
was vortexed for 3 min (Zx3, VelpScientifica, Usmate, Italy) and warmed three times in a 
water bath at 40 ± 2°C for 3 min before to be extruded through a 200 nm polycarbonate filter 
(19 cycles).  
Pegylation was introduced by adding a 2% molar of pegylated-lipid (DSPE-PEG2000) respect 
to DOTAP, using two different procedures.  
Conventional pegylated liposome (C-PEG-Liposome) was formulated using the above 
reported procedure simply mixing DOTAP (4.6 mg) with DSPE-PEG2000 (0.4 mg) in order to 
have a 2% molar of DSPE-PEG. 
Post-pegylated liposome (P-PEG-Liposome) was formed incubating Liposome with 
preformed DSPE-PEG2000 micelles. Briefly, DSPE-PEG2000 micelles were formulated drying 
under vacuum a solution of 1 mg of DSPE-PEG2000 in chloroform (0.5 mL). The film 
  
obtained was further dried in vacuum (10 mmHg) overnight and then rehydrated with water 
until reaching a 1 mM suspension. The micelles were submitted to three cycles of bath 
sonication (each cycle 2 min) and warmed in a water bath at 50 ± 2°C for 5 min. The 
suspension was then equilibrated overnight at 8°C under dark. To form P-PEG-Liposome, 
DSPE-PEG2000 micelles were diluted above CMC (20 µM) and mixed to Liposome in a water 
bath at 37 ± 1°C under gently agitation (2% molar of DSPE-PEG respect to DOTAP was used 
in this experiments).  
A concentration of 5% molar of DSPE-PEG respect to DOTAP has also been tested in an 
attempt to optimize the formative parameters. 
 
2.3 Preparation of Lipoplexes 
All lipoplexes were formulated by using 1.5 mM liposome suspension and 4 mM siRNA 
solution working in low ionic strength (I<0.1 mmol/L; potassium acetate, HEPES-KOH at pH 
7.4) to optimize complexation [31]. As previously reported [32, 33], the complexation ratio 
between siRNA and DOTAP was maintained at 1:100 molar (N/P ratio of 1/2).  
To form cationic lipoplexes (Lipoplexes), an aliquot of liposome formulation containing 20 
nmol of Liposome was added to 0.2 nmol of each siRNA duplex. Lipoplexes were simply 
formed by incubating for 10 min. at r.t. the mixture previously pipetted up and down 5 times. 
Lipoplexes were named as “Lipoplex(a)”, ”Lipoplex(b)” or “Lipoplex(c)” according to the 
duplex used (siRNAa, siRNAb or siRNAc). 
Conventional pegylated lipoplex (C-PEG-Lipoplexes) were formed as previously described 
for Lipoplexes but using preformed pegylated liposome (C-PEG-Liposome). Also in this case, 
C-PEG-Lipoplexes were named as “C-PEG-Lipoplex(a)”, ”C-PEG-Lipoplex(b)” or “C-PEG-
Lipoplex(c)” according to the duplex used (siRNAa, siRNAb or siRNAc). 
Post-pegylated lipoplex (P-PEG-Lipoplexes) were formed starting from Lipoplexes. 
Lipoplexes were incubated with preformed DSPE-PEG2000 micelles in a water bath at 37 ± 
1°C for 1 h under gently mixing, as described for P-PEG-Liposome. P-PEG-Lipoplexes were 
named as “P-PEG-Lipoplex(a)”, “P-PEG-Lipoplex(b)” or “P-PEG-Lipoplexe(c)” according to 
the duplex used (siRNAa, siRNAb or siRNAc). 
All lipoplexes were formulated in at least 2 lots and used for experiments within 1 h from the 
preparation. 
 
A description of Liposomes and Lipoplexes composition is reported in supplementary, T1. 
 
  
 
2.4 Physicochemical characterization of samples (Liposomes and Lipoplexes) 
2.4.1  Photon correlation spectroscopy (PCS) Mean particle size (Z-Average), size 
distribution and polydispersivity index (PDI) were determined at r.t. in water (pH 6) or in cell 
cultured medium (RPMI added with FBS) using a Zetasizer Nano ZS (Malvern, UK). The 
results were expressed also as intensity distribution, i.e. the size below which is placed the 
50% [D(50)] and 90% [D(90)] of all the particles. The zeta potential was measured in water 
(pH 6) at r.t. using the same equipment with a combination of laser Doppler velocimetry and 
phase analysis light scattering (PALS). Before the analyses, samples were diluted at 100 
µg/mL of lipid. 
 
2.4.2  Atomic force microscopy (AFM) The morphology of the samples was evaluated at r.t. 
with a Nanoscope IIIa microscope (Digital Instruments, Tonawanda, NY, USA) equipped 
with a commercial silicon tip-cantilever (tip diameter, 5–10 nm; stiffness, 40Nm-1; resonance 
frequency, 150 KHz). The height and the phase imaging data were simultaneously acquired. 
All the samples were analyzed without dilution at a scan rate of 1 Hz over a selected area 
using freshly cleaved mica as the substrate. The force applied to the surface was roughly 
adjusted by the ratio between the engaged or set point amplitude (Asp) and the free air ampli-
tude (A0). Images were processed and analyzed by using a program obtained from Gwyddion 
[34]. 
 
2.4.3 Transmission electron microscopy (TEM) The structural assembly of lipidic 
structures was analyzed by using negative staining electron microscopy (NS-TEM). Briefly, a 
drop of sample was placed on a 200-mesh formvar copper grid (TABB Laboratories 
Equipment, Berks, UK) and allowed to adsorb. The water surplus was removed by a filter 
paper. Then, a drop of 2% (w/v) aqueous solution of uranyl acetate was added and incubated 
for 5 min. Finally the aqueous solution surplus was removed by a blotting paper and the dried 
sample was observed by TEM (model JEM 2010; JEOL, Peabody, MA, USA) operating at an 
acceleration voltage of 200 KV. 
 
2.5. Evaluation of loading efficiency (complexation efficiency) 
The complexation efficiency was evaluated using a 5% (w/v) agarose gel electrophoresis 
analysis. For all the samples, 0.1 nmol of each siRNA duplex were complexed to liposomes at 
1:100 molar ratio (genetic material:cationic lipid) and run for 1 h at 100 V in TBE buffer 
  
(0.045 M tris-borate, pH 8.3 and 0.001 M EDTA) along with different amounts of free 
siRNA. The “loading” buffer was added to each sample. The non-complexed siRNA, that 
migrates as free siRNA during the electrophoresis analysis, was visualized under UV light 
(302 nm) after staining with ethidium bromide. The non-complexed siRNA was then 
quantified by using gel quantification software (Quantity One, IV Version, BIORAD 
Laboratories, Hercules, CA, USA). Loading efficiency was calculated comparing the intensity 
of the band of non-complexed siRNA in the sample with those of free siRNA at three 
different concentrations (0.01, 0.05 and 0.1 nmol). Data were expressed as complexation 
efficiency applying the following formula: 
Complexation Efficiency % = [(0.1 – non-complexed siRNA nmol) *100]/0.1 
Assay was carried out twice for each preparation batch. 
 
2.6  Cell experiments 
2.6.1 In vitro cell line HHV-8 positive PEL cell lines (namely BCBL-1 and CRO-AP/3) were 
cultured in RPMI-1640 medium supplemented with 10% (v/v) of heat-inactivated fetal bovine 
serum (FBS), L-glutamine 1 mM and antibiotics (complete medium). Cell culture was 
maintained at 37°C in a humidified incubator with 5% CO2 atmosphere.  
Before the transfection experiments, density gradient separation procedure was used to isolate 
and separate viable cells and naturally apoptotic cells [35]. Briefly, the cell suspension was 
diluted by addition of an equal volume of 0.9% (w/v) NaCl aqueous solution. The dilute 
suspension was  laid over a mixture of sodium diatrizoate (9.1%, w/v) and polysaccharide 
(5.7%, w/v) solution (density, 1.007 g/mL; osmolarity, 290 mOsm) and centrifuged at 1,800 
rpm for 25 min at r.t.. After centrifugation, the viable cells formed a distinct band at the 
sample/solution interface, while apoptotic/dead cells and cell debris were concentrated on the 
bottom. The viable cells were removed from the interface, twice washed using culture 
medium and re-seeded. Using this technique, the negative controls showed very low levels of 
dead cells (PEL cell viability >95%).  
 
2.6.2 Transfection experiments To carry out the transfection experiments, 1.25 × 105 cells 
were seeded in a total volume of 0.1 mL of complete culture medium (supplemented with 
2.5% of FBS) in a 24 wells plate. 
Initially, empty liposomes (Liposome, P-PEG-Liposome and C-PEG-Liposome) were added 
on cells at different concentrations (5, 10 and 20 µM) to identify the carrier concentrations 
without cytotoxic effects on the PEL cell line. Afterwards, complexes were separately formed 
  
in function of the three siRNA [Lipoplex(a), Lipoplex(b), Lipoplex(c); C-PEG- Lipoplex(a), 
C-PEG- Lipoplex(b), C-PEG- Lipoplex(c); P-PEG- Lipoplex(a), P-PEG- Lipoplex(b), P-
PEG- Lipoplex(c)]. The cells were transfected by the mix obtained combining each single 
type of complex that is generally defined Lipoplexes, C-PEG- Lipoplexes and P-PEG- 
Lipoplexes. As control, a combination of free siRNAs (siRNAa, siRNAb or siRNAc) was 
tested. Treated cells were re-incubated at 37 ± 0.1°C /CO2 5%, adding 0.4 mL of complete 
medium (supplemented with 5% of FBS) after 1 h. 
 
2.6.3 Analysis of cell cytotoxicity Cell viability and cell density were recorded by flow 
cytometry (FacsCalibur, BD Biosciences, CA, USA), 42 h after transfection. After this 
incubation time, the cells were gently re-suspended and analyzed without any treatment. The 
instrument was equipped with a 15mW 488nm air-cooled argon laser (for full details, please 
refer to the Supplementary Information – Methods).  
Alternatively, PEL viability was assayed by staining with Annexin V/Propidium Iodide (PI) 
(Miltenyi Biotech, Bergisch Gladbach, Germany), in accordance with manufacturer’s instructions 
(for full details, please refer to the Supplementary Information – Methods).  
Data were analyzed by CellQuest (BD Biosciences) and Summit software (Dako Colorado, 
Fort Collins, CO, USA).  
 
2.6.4 Western blot analysis As Blimp-1 mRNA and protein have half-lives of <2 and 4 hours 
respectively [35], level of protein was measured by Western blot analysis 15 h after lipoplexes 
transfection. 
Total cell lysates were obtained through Mammalian Cell Extraction Kit (BioVision), 
performed according to the manufacturer’s instructions. Protein content of the lysates was 
assessed by the Bradford assay and equalized in order to load 20 or 30 µg of protein per well. 
Proteins were separated by Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE), under reducing condition, using 8% precast gels (Biorad). Gels were run until 
the protein marker (Biorad Precision Plus Protein Dual Color) reached the bottom of the gel, 
using a standard Tris-Glycine-SDS buffer. Proteins were then transferred onto nitrocellulose 
membranes in a standard transfer buffer with 20% methanol, using a wet blotting system. The 
resulting membranes were blocked in 5% milk (Biorad) and then incubated overnight at 4°C 
with antibodies specific to Blimp-1 (C14A4, Cell Signaling) and β-Tubulin (9F3, Cell 
Signaling). On the following day, the membranes were washed with TBS-Tween 20 and then 
incubated for 1 h with appropriate horseradish peroxidase-conjugated secondary antibodies 
  
(donkey anti-rabbit IgG, Amersham Biosciences). After further washing out the 
immunoreactive solution, proteins were detected by the enhanced chemioluminescence 
system (ECL) (Biorad) and the chemiluminescent signal was capture using ChemiDoc XRS + 
Imaging system (Biorad). Band intensity of the target proteins was evaluated through the 
Image Lab 3.0 Software (Biorad). Target protein levels were normalized using β-Tubulin as 
loading control protein. 
 
 2.7 Statistical analysis 
All data were expressed as averages with standard deviations. Mean comparisons were 
performed by the Student t-test. The difference was considered significant when the p-value 
was less than 0.05. 
 
3. RESULTS  
3.1. Physicochemical characterization of Lipoplexes, C-PEG Lipoplexes and P PEG 
Lipoplexes 
Lipoplexes were chosen as references considering their efficiency in therapeutic siRNA 
delivery into PEL cells after intraperitoneally administration in PEL mice. Also the specificity 
of silencing mediated by siRNAs anti BLIMP-1 was previously supported by in vitro 
experiments by using a mock siRNA [12]. The Z-Average, PDI, zeta potential of the samples 
are reported in Table 1.  
Cationic liposome (Liposome) and siRNAa formed stable and monodisperse (PDI of about 
0.05) complex with a Z-Average of about 300 nm. Both siRNAb and siRNAc rearranged with 
Liposome forming complexes with higher mean diameter (Z-Average up to 400 nm) and 
polidispersivity index (PDI>0.1) if compared with Lipoplex(a). Generally, zeta potential of 
Liposome (about 42 mV) strongly decreased after complexation (about 20mV). The 
electrostatic interaction between siRNA and Liposome induces the reorganization of lipids 
around the genetic material masking the positive charge of cationic lipids. 
By AFM observation, Lipoplexes appeared as compact lipid-based structures with irregular 
shape and surface (Figure 1,a). Applying TEM analysis (Figure 1,b), Lipoplexes showed a 
complicated reorganization of lipids around the genetic materials while starting liposomes 
appeared as homogeneous vesicles delimited by a contrasted layer (Figure 1,c). No free 
duplex was detectable by both the microscopic analyses. 
 
  
Conventional pegylated lipoplexes (C-PEG-Lipoplexes), appeared as large structures with a 
wide size distribution and a surface charge proximally to the neutrality (see Table 1). Starting 
conventional pegylated liposome (C-PEG-Liposome) was stable without remarkable 
difference in the particle size (about 140 nm with a PDI value near 0.1) respect to the cationic 
liposome. Moreover, zeta potential appeared only partially reduced by the presence of PEG 
moieties on the surface (Table 1). Upon mixing with siRNA, the particle size of pegylated 
complexes increased from  130 ± 15 nm of C-PEG-Liposome to 1,300  ± 200 nm, 2,500 ± 450 
nm and 1,400 ± 230 nm for C-PEG-Lipoplex(a), C-PEG-Lipoplex(b) and C-PEG-Lipoplex(c), 
respectively. The PDI (>0.3) of these formulations suggested the presence of a heterogeneous 
population. Dimensional distribution (Figure S1) identified a bimodal formulation 
characterized by two defined and narrow peaks: the first at low values is typical of un-
complexed pegylated liposomes while the second, higher than 1 µm, is probably associated 
with irregular aggregates between C-PEG-Liposome and siRNA. zeta potential significantly 
decreased from 33±1 mV (C-PEG-Liposome) to about 6±1 mV for all the three C-PEG-
Lipoplexes. These findings suggested the presence of adsorbed siRNA on the liposomal 
surface. According with the PCS analysis, both AFM and TEM observations confirmed well 
detectable morphological differences between Lipoplexes and C-PEG-Lipoplexes. C-PEG-
Lipoplexes were characterized by the aggregation of C-PEG-Liposome around the siRNAs 
molecules, forming complicated complexes in which both genetic and un-formed materials 
were detectable (Figure 1,d and 1,e). The presence of non-complexed and docked siRNA 
fragments on liposomal surface suggested an unstable complexation. 
 
Similarly to cationic lipoplexes (Lipoplexes), post-pegylated lipoplexes (P-PEG-Lipoplexes) 
were stable and monodisperse structures with the size ranging from 300 to 420 nm, and a low 
PDI value (< 0.1). DSPE-PEG2000 was insert on preformed complexes (Lipoplexes) under 
conditions that allow the transfer of lipo-polymer from micelles to the lipoplexes (37°C, under 
agitation); after the incubation zeta potential values resulted lower than those of un-modified 
Lipoplexes and with narrow range (from 10 to 12 mV), suggesting the presence of an 
homogeneous PEG coverage of the complex surface. AFM images (Figure 1, g) reported 
compact structures with symmetrical shape and regular surface with only few aggregates. 
TEM images (Figure 1,h) well identified the architecture of P-PEG-Lipoplexes, i.e. a) high 
electron dense core of preformed Lipoplexes, in which the lipidic lamellae typical of 
liposomes and the encapsulated siRNAs (indicate by arrows) were identifiable; b) the laminar 
  
texture of the outer layers that is the evidence of a compact coverage characterized by a bright 
contrast due to the pegylation [31]. 
 
 
 
Table 1: Physicochemical and technological parameters of liposomes  and lipoplexes. Values are the mean 
±S.D. (n = 9).  All the increments in mean diameter of lipoplexes resulted significant respect to liposomes.  
Differences between the complexes generated starting from liposome formulations and three different siRNA 
(Lipoplex(a), Lipoplex(b), Lipoplex(c) and P-PEG-Lipoplex(a), P-PEG-Lipoplex(b), P-PEG-Lipoplex(c)) 
resulted not significant accordingly to Student t-test 
  
 
 
Fig.1: Morphological characterization of samples.  AFM height images of a) Lipoplex(a), d)C-PEG- Lipoplex 
(a) and g) P-PEG- Lipoplex (a). TEM images of b) Lipoplex (a), c)Liposome, e)C-PEG-Lipoplex(a), f)C-PEG-
Liposome, h)P-PEG-Lipoplex, i) P-PEG-Liposome.  
 
3.2. Influence of PEGylation on siRNAs complexation capacity. 
Lipoplexes, C-PEG-Lipoplexes and P-PEG-Lipoplexes obtained by using siRNAa, siRNAb 
and siRNAc were subjected to agarose gel electrophoresis to detect non-complexed siRNA 
and to measure the complexation efficiency of the carriers. 
Figure 2 reports the runs of free siRNAs, Lipoplexes, C-PEG-Lipoplexes and P-PEG-
Lipoplexes and the quantification of the non-complexed siRNA.  
Free siRNA (0.1 nmol; control) and the non-complexed siRNA migrated as a single bright 
band wholly detectable at the end of the run after ethidium bromide reaction (Figure 2).  
siRNA were almost completely taken up in Lipoplexes (Figure 2). Only slight shadows 
related to non-complexed active were detectable at the end of the run. Also the quantification 
assay demonstrated that the efficiency of complexation was greater than 90% for each 
  
complex analyzed. Classic pegylated lipoplexes (C-PEG-Lipoplexes) did not form stable 
complexes with siRNA as proven by the great amount of un-bound siRNA migrated during 
the analysis. Complexation efficiency was, in all cases, less than 15%. Differently, post-
pegylated lipoplexes (P-PEG-Lipoplexes) were able to stabilize high amount of siRNA as 
revealed by the faint brightness of bands of the related non-complexed siRNA. The 
complexation of siRNAa and siRNAb was close to 80% while that of siRNAc decreased to 
about 70%.  
 
 
 
Fig 2: Complexation efficiency of lipoplexes: a) agarose gel electrophoreses of lipoplexes; for each line the 
same amount (0.1nmoles) of siRNAa (lane a), siRNAb (lane b) and siRNAc (lane c) free and complexed, were 
loaded. Only non-complexed siRNA resulted able to migrate thought the gel being visible at the end of the run. 
b) quantification of complexation efficiency by Quantity One software. Data represent mean value of three 
independent experiments performed with different lipidic formulations. 
 
 
 
 
3.3. Toxicity of lipidic carriers 
  
The cell density and the cell viability over the values of 90% and 80%, respectively, were 
maintained until the concentration of 10 µM of cationic lipids transfected by using cationic 
liposome (Liposome) or pegylated liposomes (C-PEG-Liposome or P-PEG-Liposome). No 
differences were observed changing the modality of PEG insertion (Figure 3).   
 
 
 
 
Fig 3:  Toxicity of liposomal formulation: a) % of viability and b) % of cell density of BCBL-1 after treatment 
with  Liposome (♦), C-PEG-Liposome (■) and P-PEG-Liposome (○). Values were normalized respect to un-
treated cells that were considered as 100% of viability and cell density (0 µM refers to negative control that was 
treated with only water). 
 
 
3.4. siRNA delivery by Lipoplexes 
To evaluate the transfection activity and the therapeutic efficiency of lipofection approach, 
both Blimp-1 silencing level and antineoplastic effects were measured BCBL-1 cells (Figures 
4 and  6). To validate the efficiency of our systems, data related to the transfection 
experiments of 100 nM of siRNA complexed performed on another PEL cell line, CRO-AP/3, 
are reported in supplementary file (Figure S5). 
  
No significant effect was observed after transfection of all free carriers (Liposome, C-PEG-
Liposome or P-PEG-Liposome) and after treatment with siRNAs free at 100 nM, which was 
the maximal concentration of siRNAs transfected. 
Initially, un-modified lipoplexes (Lipoplexes) were evaluated. Testing two different 
concentrations (50 and 100 nM) of complexed siRNA, corresponding to 5 and 10 µM of lipid, 
respectively, a cytotoxic dose-dependent effect associated with a Blimp-1 level reduction was 
measured. Cell density decreased to 52 ± 3% and 14 ± 9% after 50 nM and 100 nM of siRNA 
complexed in Lipoplexes, respectively (Figure 4,b). Moreover, the cell viability decreased 
until to 32 ± 1% for the higher siRNA concentration (100 nM).  
Reduction in cell viability was confirmed by the increase in Annexine V and PI positive cells 
indicating a high level of cells in end stage apoptosis or dead (Figure 4,c).  
As evident in Figure 4,a, the reduction of Blimp-1 level was about 20% and 45% after 
transfection with 50 nM and 100 nM of siRNAs complexed, respectively.  
 
 
 
 
  
 
Fig. 4: siRNAs transfection in BCBL-1 mediated by Lipoplexes: a) Western blot reports the Blimp-1 silencing 
mediated by Lipoplexes using β-tubulin as control. Protein levels in un-treated cells were compared to that 
observed after different concentrations of siRNAs (50 nM and 100 nM) transfected by Lipoplex (complex) and 
measured 15 hours after transfection. Treatment with Liposome without siRNA is also reported. Data represent 
mean values of three independent experiments. b) % of both cell density (gray bars) and viability (white bar) 
recorded 48 hours after treatment with siRNA alone, Liposome and Lipoplexes at different concentrations of 
siRNA transferred (50 and 100 nM). Results are normalized to control represented by un-treated cells 
maintained in the same cellular condition.  
Data represent mean values of three independent experiments, performed in triplicate wells for each condition.  
Statistical analyses was performed:  
* p<0.05 vs siRNA non-complexed; ** p<0.02 vs siRNA non-complexed. Bars reported the analyses compared 
to the negative control Liposome  
c) Annexine/Pi analyses: cells in the lower left quadrant (Annexin V−/PI−) are viable, those in the lower right 
quadrant (Annexin V+/PI−) are early apoptotic and those in the upper right quadrants (Annexin V+/PI+) are 
late apoptotic or necrotic. 
  
 
 
The inability to protect and stabilize siRNAs during complexation made inefficient the 
transfection mediated by complexes prepared with conventional pegylated liposome (C-PEG-
Lipoplexes) (Figure 5).  
 
Fig. 5: siRNAs transfection in BCBL-1 mediated by C-PEG-Lipoplexes:  % of cell density (gray bars) and 
viability (white bar) of cells treated with siRNAs alone or C-PEG-Liposomes and C-PEG-Lipoplex at different 
concentrations of siRNAs transferred (50 and 100 nM). Results are normalized to control represented by un-
treated cells maintained in the same cellular condition. Data represent mean values of three independent 
experiments, performed in triplicate wells for each condition.  
Statistical analyses was performed: * p<0.05 vs siRNA non-complexed; ** p<0.02 vs siRNA non-complexed 
 
On the contrary, the efficiency of siRNA-mediated gene silencing after transfection by using 
post-pegylated lipoplexes (P-PEG-Lipoplexes) was confirmed both by cytometric and western 
blot analysis. 
P-PEG-Lipoplexes produced a significant cytotoxic effect both in BCBL-1 and CRO-AP/3 
cell lines (Figure 6,b and Supplementary Figure S5).  
In details, after treatment with P-PEG-Lipoplexes, BCBL-1 cells underwent to a massive 
apoptosis being positive to Annexine V/PI as reported in Figure 6,c. A dose-dependent 
reduction of cell density (from 56±7 % to 26±7% after treatment with 50 and 100 nM of 
siRNAs respectively) and cell viability (from 64±4% to 36±8% after treatment with 50 and 
100 nM of siRNAs respectively) was observed (Figure 6,b).  
  
Also in this case, the quantification of Blimp-1 silencing reveled a reduction  of the protein 
level,  which resulted approximately 10% and 40% respect to un-treated cells, using 50 nM 
and 100 nM of siRNAs complexed, respectively (Figure 6,a). 
 
 
 
Fig 6: siRNAs transfection in BCBL-1 mediated by P-PEG-Lipoplexes: a) Western blot reports the Blimp-1 
silencing mediated by P-PEG-Lipoplexes using β-tubulin as control. Protein levels in un-treated cells were 
compared to that observed after different concentration of siRNAs (50 nM and 100 nM) transfected by P-PEG-
Lipoplexes (complex), measured at 15 hours after transfection. Treatment with P-PEG-Liposome without siRNAs 
as reported. Data represent mean values of three independent experiments. b) % of both cell density (gray bars) 
and viability (white bar) 48 hours after treatment with siRNAs alone , P-PEG-Liposome and P-PEG-Lipoplexes 
at different concentrations of siRNAs transferred (50 and 100 nM). Results are normalized to control 
represented by un-treated cells maintained in the same cellular condition. Data represent mean values of three 
independent experiments, performed in triplicate wells for each condition. Statistical analyses was performed:  
* p<0.05 vs siRNAs non-complexed; ** p<0.02 vs siRNAs non-complexed. Bars reported the analyses compared 
to the negative control Liposome  
c) Annexine/Pi analyses: cells in the lower left quadrant (Annexin V−/PI−) are viable, those in the lower right 
quadrant (Annexin V+/PI−) are early apoptotic and those in the upper right quadrants (Annexin V+/PI+) are 
late apoptotic or necrotic. 
 
  
Interestingly the transfection ability of both Lipoplexes and P-PEG-Lipoplexes did not 
seemed to be related to the presence of serum. The cytotoxicity resulted substantially 
unchanged after transfection at high FBS concentrations, thus supporting the in vivo 
translatability (see supplementary S2). 
Taking advantage of the greater transfection ability of P-PEG-Lipoplexes made with 2% 
molar of DSPE-PEG2000, high amount of DSPE-PEG was also tested, formulating lipoplexes 
with 5% molar of DSPE-PEG2000 (5% P-PEG-Lipoplex).  
Despite of a high complexation efficiency (value in the range of 80-90%, Figure S3,a), the 
deposition of 5% molar of DSPE-PEG2000 micelles on preformed Lipoplexes decreased the 
efficiency to transfect siRNAs (Figure S3,b). Particularly, the same concentration of siRNAs 
transfected using P-PEG-Lipoplexes with a 5% of PEG coverage did not produce the same 
silencing obtained with complexes pegylated with a 2% PEG. 
Cells maintained high cell density (over 70% or over 40%) after the transfection of 50 nM or 
100 nM of siRNAs in 5% P-PEG-Lipoplexes, respectively. This data appeared attenuate if 
compared with the transfection mediated by 2% P-PEG-Lipoplexes (56% and 26% 
respectively).   
At the same manner, the effect on cells viability of siRNAs transfected by 5% P-PEG-
Lipoplexes was attenuated if compared with 2% P-PEG-Lipoplexes (the value ranged 
between 50 and 60% for all the concentrations of the siRNAs used) probably by the presence 
of highly concentrated coverage.  
 
4. Discussion  
Recently, experimental evidences suggested Blimp-1 as one of the possible target protein in 
PEL treatment. Indeed, the silencing of this transcriptional factor, that plays an important role 
during plasmacytic differentiation and is highly expressed both in normal and transformed 
plasma cells [36], seems to induce an important therapeutic response against PEL and other 
lymphoproliferative diseases [37].  
The transfection of anti Blimp-1 siRNAs mediated by cationic lipidic complexes (Lipoplexes) 
was associated to a rapid induction of apoptosis and cytotoxic effect in PEL cell line. Those 
results were also confirmed during in vivo studies on PEL murine model in which we have 
observed a significant improvement in overall survival after intraperitoneally administration 
of Lipoplexes [12].  
  
Lipoplexes clearly described the new entities formed between siRNAs and liposomes. 
Complexation of siRNAs with lipids transformed unilamellar cationic liposomes into 
supramolecular assemblies. These articulated concentric multilamellar structures can be 
compared to the well-known ‘‘sandwich’’ structures [33,38], in which siRNA molecules 
resulted un-detectable because they are efficiently stabilized between the lipidic layers.  
The in vivo destiny of cationic complexes after IV administration is largely described, these 
structures rapidly interact with proteins leading to the formation of a dense coverage (protein 
corona) able to drive the biological features (increasing the RES uptake), promote the 
aggregation and influence both the geometry and the packaging of gene material into the 
complex [39].  
Upon incubation with high percentage of FBS at 37°C, an increase of medium diameter (Z-
Average) of Lipoplexes occurred within a few min, suggesting serum proteins coating the 
complex or penetrating into the complex  to various extents (see Supplementary, figure S3,a). 
Of note, as reference, Lipoplexes incubated in the absence of serum did not show any 
aggregation or significant changes in size measures. Notwithstanding the interaction with 
serum components that lead to a size increase, the transfection efficiency of Lipoplexes was 
conserved also at high amount of FBS in medium (up to 10%, see supplementary Figure S2) 
suggesting the maintenance of the siRNA-lipids packaging.  
In order to stabilize lipidic complexes we have investigated the PEGylation procedure that is 
commonly applied to extend the systemic circulatory lifetime without both toxicity and 
induction of immune response [40]. 
Preformed pegylated liposome resulted unable to form stable complexes with siRNAs. PEG 
creates an hydrophilic barrier that hampered the penetration of gene material through lipid 
bilayers, thus in C-PEG-Lipoplexes, siRNAs molecules resulted prevalently exposed on the 
surface of lipidic structures, unprotected and easily degradable from serum.  
To avoid interference of PEG during the lipoplexes formation, a post pegylation strategy was 
used. In this case, siRNAs were previously mixed with Liposome assuring an efficient 
electrostatic interaction leading to siRNA stabilization into cationic core, then, incubation 
with DSPE micelles occurred. The insertion of poly(ethylene glycol) derivatized phospholipid 
into pre-formed liposomes is reported in literature [41,42].  
When in aqueous medium, lipid monomers are known to transfer from one lipid phase to 
another, in a time and temperature dependent mode [43].  Referring to PEG-DSPE, the 
micelles demonstrated good stability at the low-temperature condensed phase (< 12°C) due 
the higher activation barrier to monomer desorption from the micelle, but the micellar state is 
  
thermodynamically unstable; increasing temperature the monomer desorption begins [44]. 
PEG transfer was then achieved at 37°C that corresponds to a temperature in which both 
micelles instability and DOTAP phase transition (Tm=5°C) occurred; incubation time was set 
at 1h to lead a thermodynamic process took place.   
Several articles suggest that the percentage of PEG (exposed on surface) needed to stabilize 
the particles ranged between 2 and 5% mol if compared to the lipidic composition [45, 46]. 
Moreover, a brush conformation of PEG moieties exposed on particle surface is the most 
suitable to reduce plasma protein inducing opsonization [40]. Our post-pegyalated complexes, 
P-PEG- Lipoplexes, with a diameter in the range 300-350 nm and only a minimal amount of 
PEG (we used 2% molar of DSPE-PEG2000 respect to DOTAP) efficiently formed and protect 
siRNAs (complexation efficiency about 80%). Even if we did not figure-out the active 
conformation of PEG, the physiochemical characterization by using advanced microscopical 
and spectroscopical analysis demonstrated the presence of the PEG moieties prevalently 
arranged on the outer layer of complexes forming a dense coverage.  As largely described, the 
presence of PEG on lipidic complex surface reduce the amount of serum protein adsorbed 
[48]. P-PEG-Lipoplexes formed using 2% of DSPE-PEG (respect to cationic lipid) resulted 
stable after incubation with different percentage (2.5%v/v and 50% v/v) of FBS, as suggested 
by the maintenance of the original formulative size (see supplementary, Figure S3,b). PEG 
coating did not interfere with the interaction and the release of siRNAs from lipoplexes into 
cells. In fact, P-PEG-Lipoplexes well mediated the siRNAs transfection, independently from 
the presence of FBS, causing BLIMP-1 inhibition and cell apoptosis (Figure 6 and 
supplementary Figure S2).  
 
5. Conclusion  
 
The post-insertion of PEG on preformed lipoplexes demonstrated great potential for masking 
siRNAs and minimizing the interaction with serum proteins. Then, P-PEG-Lipoplexes will be 
tested in in vivo studies evaluating both the ability to stabilize and to efficiently deliver 
siRNAs in PEL animal model. The safety of the carriers  and the cytotoxic effect exerted by 
siRNAs should be evaluated to define the clinical applicability of this approach.  
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